A consensus Covid-19 immune signature combines immuno-protection with discrete sepsis-like traits associated with poor prognosis

Person-to-person transmission of SARS-CoV-2 virus has triggered a global emergency because of its potential to cause life-threatening Covid-19 disease. By comparison to pauci-symptomatic virus clearance by most individuals, Covid-19 has been proposed to reflect insufficient and/or pathologically exaggerated immune responses. Here we identify a consensus peripheral blood immune signature across 63 hospital-treated Covid-19 patients who were otherwise highly heterogeneous. The core signature conspicuously blended adaptive B cell responses typical of virus infection or vaccination with discrete traits hitherto associated with sepsis, including monocyte and dendritic cell dampening, and hyperactivation and depletion of discrete T cell subsets. This blending of immuno-protective and immuno-pathogenic potentials was exemplified by near-universal CXCL10/IP10 upregulation, as occurred in SARS1 and MERS. Moreover, specific parameters including CXCL10/IP10 over-expression, T cell proliferation, and basophil and plasmacytoid dendritic cell depletion correlated, often prognostically, with Covid-19 progression, collectively composing a resource to inform SARS-CoV-2 pathobiology and risk-based patient stratification.

[1]  S. Weiss Forty years with coronaviruses , 2020, The Journal of experimental medicine.

[2]  Hong Yang,et al.  Lack of Peripheral Memory B Cell Responses in Recovered Patients with Severe Acute Respiratory Syndrome: A Six-Year Follow-Up Study , 2011, The Journal of Immunology.

[3]  M. Tsai,et al.  Basophil-derived tumor necrosis factor can enhance survival in a sepsis model in mice , 2018, Nature Immunology.

[4]  Carl H. June,et al.  Cytokine release syndrome in severe COVID-19 , 2020, Science.

[5]  Aaron J. Wilk,et al.  A single-cell atlas of the peripheral immune response to severe COVID-19 , 2020, medRxiv.

[6]  A. Bertoletti,et al.  Memory T cell responses targeting the SARS coronavirus persist up to 11 years post-infection , 2016, Vaccine.

[7]  Sasikanth Manne,et al.  Deep immune profiling of COVID-19 patients reveals patient heterogeneity and distinct immunotypes with implications for therapeutic interventions , 2020, bioRxiv.

[8]  J. Manus [Lessons from SARS]. , 2003, Revue de l'infirmiere.

[9]  Reiner Schulz,et al.  Adjuvanted influenza-H1N1 vaccination reveals lymphoid signatures of age-dependent early responses and of clinical adverse events , 2016, Nature Immunology.

[10]  A. Casrouge,et al.  Discrimination of agonist and antagonist forms of CXCL10 in biological samples , 2012, Clinical and experimental immunology.

[11]  Lijuan Xiong,et al.  Longitudinal characteristics of lymphocyte responses and cytokine profiles in the peripheral blood of SARS-CoV-2 infected patients , 2020, EBioMedicine.

[12]  Aaron M. Rosenfeld,et al.  Immunologic perturbations in severe COVID-19/SARS-CoV-2 infection , 2020, bioRxiv.

[13]  Michel Theron,et al.  An interferon‐γ‐related cytokine storm in SARS patients† , 2004, Journal of medical virology.

[14]  Ritesh Gupta,et al.  Comorbidities in COVID-19: Outcomes in hypertensive cohort and controversies with renin angiotensin system blockers , 2020, Diabetes & Metabolic Syndrome: Clinical Research & Reviews.

[15]  Zhigang Tian,et al.  Functional exhaustion of antiviral lymphocytes in COVID-19 patients , 2020, Cellular & Molecular Immunology.

[16]  Jing Yuan,et al.  Treatment of 5 Critically Ill Patients With COVID-19 With Convalescent Plasma. , 2020, JAMA.

[17]  S. Lapinsky,et al.  Pro/con clinical debate: Steroids are a key component in the treatment of SARS , 2004, Critical care.

[18]  Lei Liu,et al.  Potent human neutralizing antibodies elicited by SARS-CoV-2 infection , 2020, bioRxiv.

[19]  P. Kresl Lessons from the Past and a Look to the Future , 2007 .

[20]  S. Perlman,et al.  Another Decade, Another Coronavirus , 2020, The New England journal of medicine.

[21]  B. Casserly,et al.  The compensatory anti-inflammatory response syndrome (CARS) in critically ill patients. , 2008, Clinics in chest medicine.

[22]  D. Chiumello,et al.  COVID-19 pneumonia: ARDS or not? , 2020, Critical Care.

[23]  M. Shankar-Hari,et al.  Goodbye SIRS? Innate, trained and adaptive immunity and pathogenesis of organ dysfunction , 2020, Medizinische Klinik - Intensivmedizin und Notfallmedizin.

[24]  Lubka T. Roumenina,et al.  Complement System Part II: Role in Immunity , 2015, Front. Immunol..

[25]  A. Folgori,et al.  Antigen‐specific CD8 T cells in cell cycle circulate in the blood after vaccination , 2019, Scandinavian journal of immunology.

[26]  R. Schwartz,et al.  Imbalanced Host Response to SARS-CoV-2 Drives Development of COVID-19 , 2020, Cell.

[27]  E. Crivellato,et al.  Mast Cells and Basophils: A Potential Link in Promoting Angiogenesis during Allergic Inflammation , 2009, International Archives of Allergy and Immunology.

[28]  Y. Hu,et al.  Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China , 2020, The Lancet.

[29]  M. Netea,et al.  Immunological memory: lessons from the past and a look to the future , 2016, Nature Reviews Immunology.

[30]  M. Kikkert,et al.  Host Factors in Coronavirus Replication , 2017, Current topics in microbiology and immunology.

[31]  Dong-Dong Wu,et al.  Dendritic Cells in Sepsis: Pathological Alterations and Therapeutic Implications , 2017, Journal of immunology research.

[32]  K. Chatterjee,et al.  Characterization of biological variation of peripheral blood immune cytome in an Indian cohort , 2019, Scientific Reports.

[33]  Sara Invitto,et al.  Current state of the science , 2015 .

[34]  J. M. Crawford,et al.  Targeting potential drivers of COVID-19: Neutrophil extracellular traps , 2020, The Journal of experimental medicine.

[35]  B. Pulendran,et al.  Dengue virus infection induces expansion of a CD14(+)CD16(+) monocyte population that stimulates plasmablast differentiation. , 2014, Cell host & microbe.

[36]  J. Joh,et al.  Immune Responses to Middle East Respiratory Syndrome Coronavirus During the Acute and Convalescent Phases of Human Infection , 2018, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[37]  Bali Pulendran,et al.  Immunological mechanisms of vaccination , 2011, Nature Immunology.

[38]  Guangyou Duan,et al.  A prospective observational cohort study , 2016 .

[39]  Kai Zhao,et al.  A pneumonia outbreak associated with a new coronavirus of probable bat origin , 2020, Nature.

[40]  I. Wakefield,et al.  Influenza vaccination and the elderly. , 1990, BMJ.

[41]  L. Saif Animal coronavirus vaccines: lessons for SARS. , 2004, Developments in biologicals.

[42]  Benjamin J. Polacco,et al.  A SARS-CoV-2 Protein Interaction Map Reveals Targets for Drug-Repurposing , 2020, Nature.

[43]  Yan Peng,et al.  Effectiveness of convalescent plasma therapy in severe COVID-19 patients , 2020, Proceedings of the National Academy of Sciences.

[44]  P. Mehta,et al.  COVID-19: consider cytokine storm syndromes and immunosuppression , 2020, The Lancet.

[45]  M. Ravid,et al.  A Six-Year Follow-up Study , 2016 .

[46]  E. Fredlund,et al.  Mass Cytometry and Topological Data Analysis Reveal Immune Parameters Associated with Complications after Allogeneic Stem Cell Transplantation. , 2017, Cell reports.

[47]  J. McElhaney,et al.  Immunosenescence: Influenza vaccination and the elderly. , 2014, Current opinion in immunology.

[48]  Miriam Merad,et al.  Pathological inflammation in patients with COVID-19: a key role for monocytes and macrophages , 2020, Nature Reviews Immunology.

[49]  Dennis Andersson,et al.  A retrospective cohort study , 2018 .

[50]  J. Greenbaum,et al.  Targets of T Cell Responses to SARS-CoV-2 Coronavirus in Humans with COVID-19 Disease and Unexposed Individuals , 2020, Cell.

[51]  K. Yuen,et al.  Clinical Characteristics of Coronavirus Disease 2019 in China , 2020, The New England journal of medicine.

[52]  Linqi Zhang,et al.  Human neutralizing antibodies elicited by SARS-CoV-2 infection , 2020, Nature.

[53]  M. Merad,et al.  Immunology of COVID-19: Current State of the Science , 2020, Immunity.

[54]  A. Hayday,et al.  Tracking immunodynamics by identification of S-G2/M-phase T cells in human peripheral blood☆☆☆ , 2020, Journal of autoimmunity.

[55]  P. Horby,et al.  Features of 20 133 UK patients in hospital with covid-19 using the ISARIC WHO Clinical Characterisation Protocol: prospective observational cohort study , 2020, BMJ.